REGULATED PRESS RELEASE published on 04/08/2024 at 23:12, 6 months 10 days ago Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. La société publie ses résultats opérationnels et financiers pour l’exercice clos le 31 décembre 2023, mettant en avant ses avancées dans le développement de traitements pour les maladies liées à l'âge Résultats Financiers Biophytis Développement Clinique Maladies Liées À L'âge Traitements
REGULATED PRESS RELEASE published on 04/08/2024 at 23:12, 6 months 10 days ago Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE published on 04/08/2024 at 23:10, 6 months 10 days ago Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone) Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024 Biophytis Étude Clinique BIO101 Obésité OBA
REGULATED PRESS RELEASE published on 04/08/2024 at 23:10, 6 months 10 days ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025 Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF published on 04/08/2024 at 23:09, 6 months 10 days ago Biophytis announces its 2023 financial results and provides an update on its activities Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF published on 04/08/2024 at 23:09, 6 months 10 days ago Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités Biophytis Financement Développement Clinique Résultats Financiers 2023 BIO101
BRIEF published on 04/08/2024 at 23:05, 6 months 10 days ago Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101 Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
BRIEF published on 04/08/2024 at 23:05, 6 months 10 days ago Biophytis annonce une étude clinique de phase 2 sur le traitement de l'obésité avec BIO101 Biophytis BIO101 Étude Clinique De Phase 2 OBA Traitement De L'obésité Agonistes Des Récepteurs GLP-1
PRESS RELEASE published on 04/08/2024 at 23:04, 6 months 10 days ago Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023 Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE published on 04/08/2024 at 23:04, 6 months 10 days ago Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
Published on 10/19/2024 at 00:20, 6 hours 18 minutes ago Bermuda Carbon Commission Debuts at Green Overseas Climate Finance Forum: Setting a Global Standard for Blue Carbon Innovation
Published on 10/18/2024 at 20:00, 10 hours 38 minutes ago Western Alaska Minerals Announces Grant of Restricted Share Units
Published on 10/18/2024 at 15:00, 15 hours 38 minutes ago Namibia Critical Metals Receives Environmental Clearance Certificate for Mining Activities on its Lofdal Heavy Rare Earth Project
Published on 10/18/2024 at 14:31, 16 hours 7 minutes ago Vicinity Motor Corp. Receives Notice from RBC of Intent to File Receivership Order on Monday, October 21, 2024
Published on 10/18/2024 at 14:00, 16 hours 38 minutes ago Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions
Published on 10/19/2024 at 05:59, 38 minutes ago Policy Address by Hong Kong SAR’s Chief Executive John Lee: Improving People’s Livelihood in Pursuit of Happiness
Published on 10/18/2024 at 22:18, 8 hours 19 minutes ago Investor Materials Ahead of Trading Resumption
Published on 10/18/2024 at 22:14, 8 hours 23 minutes ago EQS-Adhoc: aap Implantate AG: Step-by-step restart of IT systems
Published on 10/18/2024 at 19:45, 10 hours 53 minutes ago Springer Nature - Exercise & Post-Stabilisation
Published on 10/18/2024 at 18:30, 12 hours 8 minutes ago For the track and the road: The new 911 GT3 and 911 GT3 with Touring package
Published on 10/18/2024 at 18:55, 11 hours 42 minutes ago LDC : Accord en vue de l’acquisition de European Convenience Food (ECF) en Allemagne.
Published on 10/18/2024 at 18:55, 11 hours 42 minutes ago LDC : Entry into an agreement for the acquisition of European Convenience Food (ECF) in Germany.
Published on 10/18/2024 at 17:45, 12 hours 53 minutes ago TINC investeert in de veilige en vlotte doorstroming van de ringweg rond Brussel (B)
Published on 10/18/2024 at 17:45, 12 hours 53 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)
Published on 10/18/2024 at 17:45, 12 hours 53 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)